Detecting heterogeneous treatment effects to guide personalized blood pressure treatment a modeling study of randomized clinical trials

Annals of Internal Medicine

Volumn 166, Issue 5, 2017, Pages 354-360

  Basu, Sanjay ^a   Sussman, Jeremy B ^b   Hayward, Rod A ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; HETEROGENEOUS TREATMENT EFFECT; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; CARDIOVASCULAR DISEASES; COMPLICATION; COMPUTER SIMULATION; HYPERTENSION; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STANDARDS;

ANTIHYPERTENSIVE AGENT;

ADULT; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COMPUTER SIMULATION; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS;

EID: 85018194357     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M16-1756     Document Type: Article

References (25)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics- 2015 update: a report from the American Heart Association. Circulation. 2015;131:e29-322. [PMID: 25520374] doi:10.1161/CIR .0000000000000152
2. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al; ACCORD Study Group. Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1575-85. [PMID: 20228401] doi:10.1056/NEJMoa1001286
3. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373:2103-16. [PMID: 26551272] doi:10.1056/NEJMoa1511939
4. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410-9. [PMID: 15983291]
5. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62. [PMID: 9635947]
6. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess. 2001;5:1-56. [PMID: 11701102]
7. Albert JM, Gadbury GL, Mascha EJ. Assessing treatment effect heterogeneity in clinical trials with blocked binary outcomes. Biom J. 2005;47:662-73. [PMID: 16385907]
8. Rothwell PM, Warlow CP. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists' Collaborative Group. Lancet. 1999;353: 2105-10. [PMID: 10382694]
9. Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol. 2006;6:18. [PMID: 16613605]
10. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroupspecific analyses; power and sample size for the interaction test. J Clin Epidemiol. 2004;57:229-36. [PMID: 15066682]
11. Burke JF, Hayward RA, Nelson JP, Kent DM. Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials. Circ Cardiovasc Qual Outcomes. 2014;7:163-9. [PMID: 24425710] doi:10.1161/CIRCOUTCOMES.113.000497
12. Burke JF, Sussman JB, Kent DM, Hayward RA. Three simple rules to ensure reasonably credible subgroup analyses. BMJ. 2015;351: h5651. [PMID: 26537915] doi:10.1136/bmj.h5651
13. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med. 2006;145:520-30. [PMID: 17015870]
14. Banach M, Aronow WS. Blood pressure j-curve: current concepts. Curr Hypertens Rep. 2012;14:556-66. [PMID: 23054894] doi: 10.1007/s11906-012-0314-3
15. Timbie JW, Hayward RA, Vijan S. Diminishing efficacy of combination therapy, response-heterogeneity, and treatment intolerance limit the attainability of tight risk factor control in patients with diabetes. Health Serv Res. 2010;45:437-56. [PMID:20070387]doi:10.1111/j .1475-6773.2009.01075.x
16. VanderWeele TJ, Knol MJ. Interpretation of subgroup analyses in randomized trials: heterogeneity versus secondary interventions. Ann Intern Med. 2011;154:680-3. [PMID: 21576536] doi:10.7326/0003-4819-154-10-201105170-00008
17. Lei H, Nahum-Shani I, Lynch K, Oslin D, Murphy SA. A "SMART" design for building individualized treatment sequences. Annu Rev Clin Psychol. 2012;8:21-48. [PMID: 22224838] doi:10.1146/annurevclinpsy- 032511-143152
18. Chakraborty B, Murphy SA. Dynamic treatment regimes. Annu Rev Stat Appl. 2014;1:447-64. doi:10.1146/annurev-statistics -022513-115553
19. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-53. [PMID: 18212285] doi:10.1161/CIRCULATIONAHA.107.699579
20. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427. [PMID: 12829555]
21. National Center for Health Statistics. National Health and Nutrition Examination Survey, 2013-2014. Atlanta: Centers for Disease Control and Prevention; 2015. Accessed at www.cdc.gov/nchs /nhanes.htm on 19 July 2016.
22. National Clinical Guideline Centre. Hypertension: The Clinical Management of Primary Hypertension in Adults, Clinical Guideline 127. London: National Institute for Health and Clinical Excellence; 2011.
23. Powers BJ, Oddone EZ, Bosworth HB. Measuring blood pressure for decision making and quality reporting. Reply to Wexler R [letter]. Ann Intern Med. 2011;155:565. Included with PubMed PMID 22007056. doi:10.7326/0003-4819-155-8-201110180-00027
24. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85. [PMID: 20704705] doi:10.1186/1745-6215-11-85
25. Dailey G, Wang E. A review of cardiovascular outcomes in the treatment of people with type 2 diabetes. Diabetes Ther. 2014;5:385-402. [PMID: 25515096] doi:10.1007/s13300-014 -0091-x